Neuromuscular Disease News

The FDA has accepted a new drug application for zilucoplan, an investigational treatment for generalized myasthenia gravis in adults who are acetylcholine receptor antibody positive, UCB announced in a released statement.

Published results showed use of a novel hip brace was effective for preventing progression of hip displacement and improving quality of life in patients with nonambulatory cerebral palsy.

CHICAGO — Stephen J. Crocker, PhD, associate professor of neuroscience at University of Connecticut School of Medicine, discusses the influence of aging on MS and remyelination, as well as the process of cellular senescence, at ANA 2022.

CHICAGO — Stephen Reich, MD, professor of neurology at the University of Maryland School of Medicine in Baltimore, spoke at ANA 2022 about clinical features of functional movement disorders and how to best identify them.

CHICAGO – Jeffrey Chamberlain, PhD, professor of neurology at the University of Washington, discussed types of gene therapy as a possible treatment for muscular dystrophy at ANA 2022.

CHICAGO – Mark Hallett, MD, chief of the motor control section at NINDS, discussed the pathology and etiology of functional neurological movement disorders at ANA 2022.

Reata Pharmaceuticals Inc. announced the FDA does not plan to hold an advisory committee meeting to discuss the company’s new drug application for an investigational therapeutic to treat Friedreich’s ataxia.

Daily treatment with risdiplam over 24 months resulted in improved motor function and achievement of developmental motor milestones in infants with type 1 spinal muscular atrophy, according to a study published in The Lancet Neurology.

Erenumab was not effective in reducing pain intensity in patients with trigeminal neuralgia, researchers reported in Lancet Neurology.

Those who survive 30 days of SARS-CoV-2 infection have an increased risk for neurological disorders after 1 year compared with those who were not infected, according to a report in Nature Medicine.